NKGN — Nkgen Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $30.67m
- $52.35m
Annual cashflow statement for Nkgen Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -23.3 | -26.8 | -83 |
| Depreciation | |||
| Non-Cash Items | 1.66 | 2.96 | 57.6 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 0.932 | 0.03 | 2.23 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Net Change in Other Assets & Liabilities | |||
| Cash from Operating Activities | -19.5 | -22.6 | -21.9 |
| Capital Expenditures | -0.459 | -0.163 | -0.048 |
| Purchase of Fixed Assets | |||
| Software Development Costs | |||
| Cash from Investing Activities | -0.459 | -0.163 | -0.048 |
| Financing Cash Flow Items | — | 0 | -15.9 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 20.2 | 22.5 | 22.2 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.152 | -0.234 | 0.159 |